Aardvark Therapeutics pauses late-stage trial testing rare disease treatment
27/02/2026 21:10
Feb 27 (Reuters) - Aardvark Therapeutics AARD.O on Friday said it is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease. (Reporting by Sneha S K; Editing by Maju Samuel) ((Sneha.SK@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark